Appointments at Merck Serono, Ascletis, Allon, Acura, Sangamo and ProStrakan – People on the move
Merck Serono, a division of Merck KGaA, has named Belen Garijo has COO and Annalisa Jenkins as Global Head of Drug Development & Medical.
Dr Garijo joins Merck Serono from Sanofi, where she was SVP of Global Operations for Europe. Dr Jenkins previously worked at Bristol-Myers Squibb, where she was SVP of Global Medical operations.
Allan Baxter has joined Sino-US drug developer Ascletis as chief strategy officer. Baxter, who has been an adviser to Ascletis for several years, joins the firm from UK drug major GlaxoSmithKline where he was SVP and global head of medicines development.
Abuse deterrent drug firm Acura Pharmaceuticals has names Robert Jones as its new CEO. Jones had been interim chief replacing Andy Reddick who passed away earlier this year.
CNS disease focused Allon Therapeutics has appointed Michael Aldridge as a director. Aldridge replaces Michael O'Brian who is retiring after serving as a board member since 2004.
Tom Stratford has been appointed as CEO of Scotland-based drug developer ProStrakan. Stratford, who will take up the post on September 1, currently serves as the firm’s VP of business development.
Netherlands-based drugmaker Norgine has named Adam Aspinall as its new global marketing director. Aspinall has worked in the drug industry for 22 year and has held positions at Amgen and Abbott Laboratories.
Generic drugmaker Lannett has appointed Robert Ehlinger as VP of logistics and chief information officer. The firm, which makes its own non-branded drugs in addition to providing contract manufacturing and packaging services, said the appointment will help drive productivity gains.
Ophthalmics-focused pharmaceutical developer Novagali Pharma has added Russell Greig, Bo Jesper Hansen, Bernard Chauvin and Nayan Greg Parekh to its supervisory board.
Sangamo BioSciences has appointed Geoffrey Nichol as executive VP of R&D he will oversee all of the company's research and clinical development activities and operations.
Antibody-based drug developer Celldex has hired Ronald Pepin as SVP and Chief Business Officer. Dr Pepin joins the firm from Shire Pharmaceuticals.
Kite Pharma has named Adrian Bot as Chief Scientific Officer. Dr Bot brings over 13 years of experience in the biopharmaceutical industry and was most head of research at MannKind.